Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
Treatments studied
Part of Lungs & breathing, Skin clinical trials.
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous one-year belimumab study (218224 or 221672) without stopping the medication early.
- If you have scleroderma, you need a patch of skin on your belly or front thigh that is not too thick, so the injection can be given there.
- You or a caregiver must be willing to give the study injections at home for the duration of the study.
- If you are a woman who could become pregnant, you must use highly effective birth control during treatment and for 4 months after the last dose.
- You must not have developed any new serious or unstable medical conditions since joining the previous study.
- You must not have had too much radiation exposure (more than 10 mSv) from work or other research in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
This Phase 1 study tests how safe belimumab is for people with idiopathic CD4 lymphopenia (low protective white blood cells) and signs of autoantibodies. It aims to learn whether the treatment is tolerable and could be a future option for people with this immune condition.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Hear when a new Connective Tissue Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.